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Abstract
The Dictyostelium ERK2 protein is transiently activated when cells are treated with the chemotactic agents cAMP or
folic acid. Activating phosphorylation is markedly inhibited in strains overexpressing the constitutively activated RasG
 .protein. This is in marked contrast to mammalian cells where the highly related mitogen-activated protein kinases MAPKs
are stimulated by Ras activation. q 1998 Published by Elsevier Science B.V.
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 .The mitogen-activated protein kinases MAPKs
play an important role in growth and development in
 w x.mammalian cells reviewed in Ref. 1 , and in addi-
tion are rapidly and transiently activated in response
w xto chemotactic agents 2,3 . They are activated by
phosphorylation on both the tyrosine and threonine
residues of a TEY motif by a dual specificity kinase,
MEK. Two MAPK homologues have been identified
w xin Dictyostelium discoideum 4,5 . One of these,
ERK2, is transiently activated in response to a pulse
w xof extracellular cAMP 6 and cells with a disrupted
erk2 gene do not show activation of adenylyl cyclase
in response to a pulse of cAMP and do not aggregate
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suggesting that ERK2 activation is intimately in-
w xvolved with signal relay 4 . This relay is essential for
aggregation of cells in response to cAMP that occurs
upon starvation in this organism.
The pathways leading to ERK2 activation in re-
sponse to cAMP in Dictyostelium have been at least
partially characterised. Examination of its activation
in strains which are lacking components of the known
signalling pathways suggests that the activation re-
quires the interaction of extracellular cAMP with
w xeither of the cAMP receptors cAR1 or cAR3 6,7 . It
has been reported that activation is dependent on the
w xGa4 subunit 7 . However, this was determined using
an immunoprecipitation kinase assay which may lack
 .specificity see below and the result needs to be
confirmed using a more direct assay. ERK2 is also
transiently activated in response to another chemo-
w xattractant, folic acid 8,9 , suggesting that its activa-
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tion plays a general role in chemotaxis in Dic-
tyostelium. The signalling pathway involved in the
activation of ERK2 by folic acid has been shown to
w xrequire the heterotrimeric G protein Ga4 9 , but
otherwise has not been well characterized.
In mammalian cells, one signalling pathway for
the activation of MAPK involves the upstream activa-
tion of the small GTP-binding protein p21ras in
response to initial stimulation of a cell surface recep-
 w x.tor reviewed in 10 . Dominant negative versions of
p21ras inhibit MAPK activation in a variety of sys-
tems and activation of p21ras has been shown to be
sufficient to activate MAPK. In this report we de-
scribe studies on ERK2 activation in response to
cAMP and folic acid in a Dictyostelium strain that
overexpresses an activated version of RasG RasG-
. w xG12T 11 , the predominant Ras protein expressed
during growth and early development. We have mea-
sured ERK2 activation by monitoring the tyrosine
phosphorylation of the TEY motif, which has been
shown to correlate with ERK2 activity in response to
w xboth cAMP and folic acid 8,9 . Our results indicate
that RasG is a negative regulator of both cAMP- and
folic acid-induced ERK2 activation.
The stimulation of the signalling pathways leading
to ERK2 activation can be monitored using an anti-
body specific for the tyrosine-phosphorylated TEY
w xmotif of this protein 8 . Tyrosine phosphorylation of
ERK2 has been shown to correlate with ERK2 activ-
w xity as detected by an in-gel kinase assay 8 . Using
the antibody assay it was shown previously that folic
acid induces a transient phosphorylation of ERK2 in
Ax2 cells, peaking at 30–60 s and returning to a
barely detectable level by 4 min. The response to
folic acid in cells expressing wild-type RasG was
w xsimilar to that observed previously for Ax2 cells 8 ,
but this response was greatly reduced in cells overex-
 .pressing constitutively activated RasG RasG-G12T
compared to cells overexpressing wild-type RasG
 .Fig. 1 . There was no significant differences in the
total amount of ERK2 in the two strains as deter-
mined using an anti-ERK antibody indicating that the
altered responses were not due to altered levels of
 .ERK2 expression data not shown .
Fig. 1. Folic acid-induced tyrosine phosphorylation of ERK2 in cells overexpressing wild-type or activated RasG. Vegetative cells from
w xstrains overexpressing wild-type RasG or activated RasG-G12T 11 were harvested from exponential phase of growth, washed in KK 2
 w x . 8buffer 20 mM potassium phosphate pH 6.1 , 2 mM MgSO and resuspended at 2=10 cellsrml in KK buffer. Cell suspensions were4 2
 .stimulated with folic acid 100 mM and lysed by boiling in Laemmli’s buffer at the indicated times following folic acid addition. Cell
 .extracts were fractionated by SDS-PAGE, transferred to a membrane and analysed for the presence of phosphorylated ERK2 PMAPK .
w x  .As described previously 8 , immunoblot analysis to detect phosphorylated MAPK PMAPK was performed using PhosphoPlus MAPK
 .antibody kit New England Biolabs , according to the manufacturer’s instructions. The antibody contained in this kit was raised against
synthetic phosphotyrosine peptide corresponding to residues 196 to 209 of human p44 MAPK and recognizes MAPK only when
 .catalytically activated by phosphorylation at Tyr 204. All filters were reblotted with anti-ERK antibody K-23, Santa Cruz Biotechnology
 .to evaluate total amount of MAPK, and the bound antibodies visualized using ECL–Western blot detection kit Amersham . The data
shown is for a single experiment, representative of four.
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The phosphorylation of ERK2 in response to cAMP
was monitored in cells which had been starved in
shaking suspension for 4 h, with a pulse of exoge-
nous cAMP added every 6 min to induce the cAMP
response system. Transformants that overexpress
wild-type RasG again showed a response that was
very similar to that previously observed in Ax2 cells
w x8 , but ERK2 phosphorylation was significantly re-
duced in cells overexpressing RasG-G12T compared
 .to cells overexpressing wild-type RasG Fig. 2 . The
total level of ERK2 protein was not significantly
different in the two strains and was not greatly
altered by developing the cells in shaking suspension
in the presence or absence of cAMP pulses data not
.shown , indicating that the reduced level of ERK2
phosphorylation was not due to an altered level of
expression of the ERK2. A small but reproducible
increase in cAMP-induced ERK2 phosphorylation
was observed in cells overexpressing the dominant
 .negative RasG-S17N data not shown . These results
suggests that RasG acts as an inhibitor of ERK2
phosphorylation in response to cAMP.
There was no significant difference between the
degree of ERK2 phosphorylation in response to cAMP
in cAMP-pulsed RasG-G12T cells compared to those
 .developed in the absence of pulses Fig. 3 . Since the
 .induction of adenylyl cyclase expression Fig. 4 and
w xcAR1 expression 11 are enhanced in RasG-G12T-
expressing cells that have been pulsed with cAMP
compared to those developed in the absence of ex-
ogenous pulses, the low level of ERK2 phosphoryla-
tion in these cells is not due to a failure to induce the
expression of the cAMP response components. It
must, therefore, be due to a direct effect of RasG-
G12T in a signalling pathway involved in the stimu-
lation of ERK2 activity.
While these experiments were in progress two
publications appeared describing work that is directly
relevant to our observations. These reports described
the influence of a different Ras protein, RasD, on
ERK2 activation. In the first of these studies, it was
shown that cAMP-induced ERK2 activation, as as-
sessed by an immunoprecipitation kinase assay, was
enhanced in strains expressing an activated version of
w xthe RasD protein, RasD-G12T 7 . This is similar to
the situation in mammalian cells where the activation
of p21ras stimulates a signalling pathway that leads
to the activation of the highly related MAPKs. In
contrast expression of an alternative form of activated
 .RasD T61Q inhibited cAMP-induced ERK2 activa-
w xtion, as determined by an in-gel kinase assay 12 .
Our results clarify this apparent discrepancy. We
have analyzed the tyrosine phosphorylation of ERK2
as a measure of its activation, and find that expres-
Fig. 2. cAMP-induced tyrosine phosphorylation of ERK2. Strains expressing RasG and RasG-G12T were induced to differentiate by
shaking in KK buffer and were pulsed with 25 nM cAMP every 6 min. After washing, cells were resuspended at 2=108 cellsrml,2
 .stimulated with cAMP 20 mM and lysed by boiling in the SDS sample buffer at the indicated time. The phosphorylated ERK2 and total
ERK2 were detected as described in the legend to Fig. 1. The data shown is for a single experiment, but similar results were obtained in
three separate, independent experiments.
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sion of activated RasG markedly inhibits ERK2 phos-
phorylation in response to cAMP, confirming that
this assay and the in-gel kinase assay are monitoring
w xthe same activation event 8,6 . It is therefore likely
that the immunoprecipitation kinase assay that showed
a stimulated activation of ERK2 in cells expressing
w xactivated RasD 7 is monitoring the activation of a
different, related kinase. The fact that RasG and
RasD produce the same marked inhibitory response
on ERK2 activation in response to cAMP is consis-
tent with the very high level of sequence identity
between the two proteins.
It is not clear how activated RasG and RasD
negatively regulate this phosphorylation of ERK2.
There is no precedent for the idea that Ras proteins
may act as negative regulators of signalling path-
ways; it is therefore more likely that Dictyostelium
Ras proteins activate a negative regulator of the
ERK2 activation pathway. Consistent with this idea is
the finding that there is a slight increase in ERK2
phosphorylation in cells expressing a dominant nega-
 .tive version of RasG RasG-S17N .
The similarity of the reduced ERK2 phosphoryla-
tion response to both cAMP and folic acid in the
Fig. 3. Comparison of ERK2 phosphorylation in RasG-overex-
pressing cells developed with and without cAMP pulsing. Cells
expressing RasG-G12T were induced to differentiate for the
 .indicated times in hours in shaking suspension in KK with2
 .  .  .q or without y cAMP pulses 25 nM every 6 min . After
washing, cells were stimulated with 20 mM cAMP and lysed at
the indicated times as described in Section 2. The amounts of
phosphorylated ERK2 relative to total ERK2 were analyzed by
Western blotting and quantified by densitometric scanning. The
data shown is from a single experiment, representative of two.
Fig. 4. Expression of aca mRNA during early development. Ax2
and RasG-G12T-expressing transformants were induced to differ-
 .  .entiate on filters A , in shaking suspension in MESrPDF B , or
in shaking suspension in MESrPDF, pulsed with 25 nM cAMP
 .every 6 min C , and were harvested at the indicated times after
the initiation of the starvation. Total RNA was analysed by
Northern blotting using aca cDNA as a probe.
rasG-G12T transformant suggests that RasG is a
negative regulator of a step common to both sig-
nalling pathways. It is known that both folic acid and
cAMP interact with seven transmembrane domain
receptors that are coupled to heterotrimeric G pro-
 w x.teins reviewed in Ref. 13 , but it is not known if
the two pathways converge prior to the activation of
ERK2 or whether they activate ERK2 by parallel but
independent pathways. The similarity of the effect of
RasG-G12T on the phosphorylation of ERK2 in re-
sponse to the two chemoattractants suggests that the
two pathways do converge. It has previously been
demonstrated that constitutive activation of the
 .cAMP-dependent protein kinase PKA increases
w xERK2 phosphorylation in response to cAMP 8,12
but has no effect on the level induced by folic acid
w x8 . This suggests that PKA can regulate a step in the
cAMP-induced pathway which is not similarly regu-
lated in the folic acid induced response. The influ-
ence of RasG described here appears to define a
common step in the two activation pathways down-
stream of the step regulated by PKA in the cAMP-in-
duced pathway. The unexpected negative effect of
RasG activation on ERK2 phosphorylation suggests
that the pathways are unlikely to be identical to those
seen in mammalian cells.
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